$AXNX

Axonics Inc

  • NASDAQ
  • Health Technology
  • Medical Specialties
  • Manufacturing
  • Surgical and Medical Instrument Manufacturing

PRICE

$57.96 -

Extented Hours

VOLUME

231,718

DAY RANGE

56.28 - 58.49

52 WEEK

38.41 - 79.81

Join Discuss about AXNX with like-minded investors

profile
@dros #droscrew
recently

RECAP 5/19 Unusual Puts: $KSS Jul 30 P $HBI Jan 10 P $GOOS Jul 17 P $RIG May-23 3 P $CCL Oct 10 P $CS Sep 7 P $FSK Jul 20 P $NKLA Aug 6 P $BHC Jan-24 3 P $AFRM Jul 25 P $INTC Jun 40 P $ONON May 17.5 P $AXNX Jul 42.5 P

67 Replies 9 👍 6 🔥

profile
@dros #droscrew
recently

+Initiations 7/12: $AOMR $ASTS $ATIP $AXNX $CNVY $CVX $INDI $JBGS $LVOX $LYEL $MOLN $SGFY $TBLA $TPVG $UPST $VERV $WKME 

98 Replies 9 👍 13 🔥

13
@13JulioCesar13 #Zona Trading
recently

$AXNX esta ya en la lista, gracias @g.lourdes35

53 Replies 10 👍 8 🔥

G.
@g.lourdes35 #Zona Trading
recently

como ven $AXNX?

45 Replies 7 👍 10 🔥

profile
@CarlosH-carvan #ivtrades
recently

$AXNX to $62

79 Replies 9 👍 7 🔥

profile
@CarlosH-carvan #ivtrades
recently

$AXNX Nov 55C

59 Replies 10 👍 14 🔥

profile
@dros #droscrew
recently

4000 $AXNX 21AUG20 $45 / $50 Call spreads bought 0.65

56 Replies 9 👍 15 🔥

profile
@dros #droscrew
recently

chart set up on the axnx pretty strong here

44 Replies 9 👍 7 🔥

profile
@dros #droscrew
recently

4000 $AXNX 21AUG20 $45 / $50 Call spreads bought 0.65

113 Replies 13 👍 6 🔥

Key Metrics

Market Cap

2.73 B

Beta

1.71

Avg. Volume

514.06 K

Shares Outstanding

47.07 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of Bulkamid®, offers a best-in-class urethral bulking agent for women with stress urinary incontinence. These conditions significantly impact quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. Stress urinary incontinence affects an estimated 20 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.

CEO: Raymond Cohen

Website:

HQ: 26 Technology Dr Irvine, 92618-2380 California

Related News